STANDARD BIOTOOLS INC (LAB) Stock Price, Quote, News and Overview
NASDAQ:LAB - Nasdaq - US34385P1084 - Common Stock - Currency: USD
LAB Quote, Performance and Key Statistics
1.23
-0.01 (-0.81%)
The current stock price of LAB is 1.23 USD. In the past month the price increased by 3.36%. In the past year, price decreased by -49.59%.
LAB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 19.48 | 161.06B | ||
| DHR | DANAHER CORP | 26.38 | 140.59B | ||
| A | AGILENT TECHNOLOGIES INC | 20.15 | 30.51B | ||
| IQV | IQVIA HOLDINGS INC | 13.53 | 26.57B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 26.12 | 22.40B | ||
| WAT | WATERS CORP | 28.7 | 20.27B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.72 | 15.22B | ||
| ILMN | ILLUMINA INC | 31.68 | 12.28B | ||
| ICLR | ICON PLC | 10.42 | 12.05B | ||
| RVTY | REVVITY INC | 19.41 | 11.43B | ||
| AVTR | AVANTOR INC | 15.5 | 10.56B | ||
| QGEN | QIAGEN N.V. | 19.48 | 9.31B |
Related stock screener links
About LAB
Company Profile
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in South San Francisco, California and currently employs 818 full-time employees. The company went IPO on 2011-02-10. The firm's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The firm provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. The company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The firm also provides differentiated multi-omics tools for research.
Company Info
STANDARD BIOTOOLS INC
2 Tower Place, Suite 2000
South San Francisco CALIFORNIA US
Employees: 537
Company Website: https://www.standardbio.com/
Investor Relations: https://investors.standardbio.com/
Phone: 16502666000
STANDARD BIOTOOLS INC / LAB FAQ
What is the stock price of STANDARD BIOTOOLS INC today?
The current stock price of LAB is 1.23 USD. The price decreased by -0.81% in the last trading session.
What is the ticker symbol for STANDARD BIOTOOLS INC stock?
The exchange symbol of STANDARD BIOTOOLS INC is LAB and it is listed on the Nasdaq exchange.
On which exchange is LAB stock listed?
LAB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for STANDARD BIOTOOLS INC stock?
7 analysts have analysed LAB and the average price target is 2.42 USD. This implies a price increase of 96.95% is expected in the next year compared to the current price of 1.23. Check the STANDARD BIOTOOLS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is STANDARD BIOTOOLS INC worth?
STANDARD BIOTOOLS INC (LAB) has a market capitalization of 466.16M USD. This makes LAB a Small Cap stock.
How many employees does STANDARD BIOTOOLS INC have?
STANDARD BIOTOOLS INC (LAB) currently has 537 employees.
What are the support and resistance levels for STANDARD BIOTOOLS INC (LAB) stock?
STANDARD BIOTOOLS INC (LAB) has a support level at 1.06 and a resistance level at 1.27. Check the full technical report for a detailed analysis of LAB support and resistance levels.
Is STANDARD BIOTOOLS INC (LAB) expected to grow?
The Revenue of STANDARD BIOTOOLS INC (LAB) is expected to decline by -1.17% in the next year. Check the estimates tab for more information on the LAB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy STANDARD BIOTOOLS INC (LAB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LAB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LAB, evaluating the profitability, health, valuation and growth aspects
- STANDARD BIOTOOLS INC (LAB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- STANDARD BIOTOOLS INC (LAB) Sales and EPS estimates to see what analysts future expectations are.
- STANDARD BIOTOOLS INC (LAB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- STANDARD BIOTOOLS INC (LAB) Insider and Institutional Ownership to learn about the owners and their transactions.
- STANDARD BIOTOOLS INC (LAB) Stock Chart to make your own analysis
- STANDARD BIOTOOLS INC (LAB) Latest news and press-releases to stay up to date.
Does STANDARD BIOTOOLS INC (LAB) stock pay dividends?
LAB does not pay a dividend.
When does STANDARD BIOTOOLS INC (LAB) report earnings?
STANDARD BIOTOOLS INC (LAB) will report earnings on 2025-05-07.
What is the Price/Earnings (PE) ratio of STANDARD BIOTOOLS INC (LAB)?
STANDARD BIOTOOLS INC (LAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.55).
What is the Short Interest ratio of STANDARD BIOTOOLS INC (LAB) stock?
The outstanding short interest for STANDARD BIOTOOLS INC (LAB) is 4.25% of its float. Check the ownership tab for more information on the LAB short interest.
LAB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to LAB. When comparing the yearly performance of all stocks, LAB is a bad performer in the overall market: 87.82% of all stocks are doing better.
LAB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LAB. While LAB seems to be doing ok healthwise, there are quite some concerns on its profitability.
LAB Financial Highlights
Over the last trailing twelve months LAB reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS increased by 35.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.2% | ||
| ROE | -39.2% | ||
| Debt/Equity | 0 |
LAB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to LAB. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 52.25% and a revenue growth -1.17% for LAB